LYRA News and Press, Lyra Therapeutics Inc. From 11/10/20

- On course to report topline Phase 2 LANTERN study results in December 2020 - Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatme...

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced the appointmen...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Lyra Therapeutics ( LYRA +0.9% ) presents data showing that LYR-210 demonstrated a significant reduction of sinonasal Type 2 inflammation in surgically naïve patients with chronic rhinosinusitis (CRS) (inflammation of the sinuses and nasal cavity). More news on: Lyra Therapeu...

Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance Findings presented at the 66 th Annual Meeting of the American Rhinologic Society WATERTOWN, Ma...

WATERTOWN, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and thro...

Lyra Therapeutics, Inc. (LYRA) Q2 2020 Earnings Conference Call August 5, 2020 04:30 PM ET Company Participants Laurence Watts - Managing Director Gilmartin Group Maria Palasis - President and Chief Executive Officer Don Elsey - Chief Financial Officer Corinne Noyes - Senior V...

Lyra Therapeutics (NASDAQ: LYRA ) : Q2 GAAP EPS of -$0.56 misses by $0.21 . More news on: Lyra Therapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

- On track to report topline Phase 2 results for LYR-210 in chronic rhinosinusitis in 4Q 2020 - - Conference call and webcast today at 4:30 p.m. ET - WATERTOWN, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focuse...